BEONE MEDICINES LTD-ADR (ONC:NASDAQ)
$373.36 7.305 (1.9956%)
Analysed BEONE MEDICINES LTD-ADR (ONC:NASDAQ) News Sources
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
01-10-2026
yahoo.com
New Strong Buy Stocks for October 15th
15-10-2026
yahoo.com
All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy
15-10-2026
yahoo.com
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
19-10-2026
yahoo.com
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
22-10-2026
yahoo.com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
23-10-2026
yahoo.com
BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.
23-10-2026
yahoo.com
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
24-10-2026
yahoo.com
BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The Narrative
24-10-2026
yahoo.com
3 Healthcare Stocks To Watch In October 2026
24-10-2026
yahoo.com
What is the current price of BEONE MEDICINES LTD-ADR (ONC:NASDAQ)?
The current price of BEONE MEDICINES LTD-ADR (ONC:NASDAQ) is $373.36.
BEONE MEDICINES LTD-ADR (ONC:NASDAQ) absolute price change since previous trading day?
The absolute price change of BEONE MEDICINES LTD-ADR (ONC:NASDAQ) since the previous trading day is $7.305.
BEONE MEDICINES LTD-ADR (ONC:NASDAQ) percentage price change since previous trading day?
The percentage price change of BEONE MEDICINES LTD-ADR (ONC:NASDAQ) since the previous trading day is 1.9956%.
What is the most recent average sentiment score for BEONE MEDICINES LTD-ADR (ONC:NASDAQ)?
The most recent average sentiment score for BEONE MEDICINES LTD-ADR (ONC:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for BEONE MEDICINES LTD-ADR (ONC:NASDAQ)?
The most recent sentiment for BEONE MEDICINES LTD-ADR (ONC:NASDAQ) is .
SEC-8K** Filing Available For BEONE MEDICINES LTD-ADR (ONC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.